---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017641"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:20:15.563453+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera achieves milestones on Series B-3 warrants, unlocking $8M gross proceeds

## Summary
- Board certified >5% YoY revenue growth (Jan-Apr 2024 vs 2023, ex-related parties) and >95% CRM adoption.
- Warrant exercise triggers $8M gross proceeds to Biofrontera.
- Shareholders approved authorized share increase from 15M to 35M at April 24 special meeting.
- Warrants expiration now 5 days after S-1 effectiveness (filed May 2) or Feb 22, 2027.

## SEC filing metadata
- accession: 0001493152-24-017641
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224017641/0001493152-24-017641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224017641/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017641
- JSON: https://secwatch.observer/filing/0001493152-24-017641.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.